A Phase 2 interventional study of modified cognitive behavioural therapy (mCBT) in Psychotic Disorders, Schizophrenia and Schizoaffective Disorder, sponsored by University of Cologne. Status unknown at 1 site in Germany. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2009-02-20.
Sponsored by University of Cologne · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Psychotic Disorders with a site in Germany — 19 open to participants now, 21 under way, 4 of them phase 3. Psychotic Disorders · Germany.
Among the 72 studies in Psychotic Disorders with a site in Germany, this one is the 47th largest by planned enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 2, and was the 12th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.
Browse Psychotic Disorders studies →19 of the 72 studies in Psychotic Disorders with a site in Germany are open now. Recruiting first, the newest first:
University of Oxford · Sites in Germany, Austria, Greece and 6 more countries
Ages 16–40
Stephanie Mehl · Sites in Germany
Ages 16–35
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Technical University of Munich · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 205 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 143 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 14 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is below the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.
Median enrollment 85 across the 65 interventional studies, 360 across the 7 observational. Of the 41 that completed or were terminated, 8 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 72 have an industry lead sponsor. The 10 most frequent:
University of Cologne is the lead sponsor of 203 studies on the registry; 26 are open to participants now.
University of Cologne has 5 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Psychotic Disorders with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
| NCT07455929Charite University, Berlin, GermanyFeasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Psychotic Disorders with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the last decade cognitive behavioural therapy (CBT) approaches for patients with schizophrenia have been developed, which where especially designed to reduce severity of positive symptoms, readmission rates, treatment non-compliance and disability. Although CBT addresses the key problems of early onset psychoses (EOP)treatment and first evaluations of CBT in adults with schizophrenia are promising, no experience with CBT in adolescents with EOP are available. Therefore the present study is conducted to develop a modified CBT (mCBT) for adolescents with EOP, to explore its acceptance and feasibility and to provide data for a realistic estimation of achievable effect size. Patients are randomized to receive either mCBT+TAU or TAU over a 9 month period. mCBT is an individual outpatient treatment of 20 session and 5 psychoeducational sessions with parents. Follow-ups for two years every 6 months are planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PANSS positive syndrome (sum of items P1-P7), assessed during the treatment phase (9 month) monthly and during the follow-up phase (2 years) every 6 months
additional symptom ratings (PSYRATS)
social functioning (GAF)
illness related events (suicide, suicide attempts, rehospitalisation, severe depressive symptom exacerbation)
quality of life (MSLQ)assessed monthly during the treatment phase (9 months) and every 6 months during the follow-up phase (2 years)
The record gives a start of May 2007 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.